Revance Therapeutics, Inc.
(NASDAQ : RVNC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
6.58%18.472.0%$259.57m
SHPGShire PLC Sponsored ADR
0.01%176.260.4%$247.57m
JAZZJazz Pharmaceuticals Plc
2.31%148.992.2%$115.41m
PRGOPerrigo Co. Plc
1.58%61.396.8%$102.79m
ENDPEndo International Plc
-0.48%12.478.9%$62.77m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.38%124.106.3%$61.53m
MNKMallinckrodt Plc
-0.36%27.9021.1%$55.04m
SAGESAGE Therapeutics, Inc.
0.32%107.739.6%$54.29m
ICPTIntercept Pharmaceuticals, Inc.
1.47%108.3218.7%$54.21m
HZNPHorizon Pharma plc
-0.05%20.567.4%$52.07m
UTHRUnited Therapeutics Corporation
1.10%114.4614.4%$47.30m
CTLTCatalent Inc
1.41%38.132.4%$41.95m
ICLRICON Plc
2.08%130.944.1%$35.01m
PTLAPortola Pharmaceuticals, Inc.
2.08%19.687.7%$34.44m
AERIAerie Pharmaceuticals, Inc.
6.02%43.526.9%$30.66m

Company Profile

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.